{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:37:19Z","timestamp":1791463039952,"version":"4.3.4"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:00:00Z","timestamp":1532044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"International Antiviral Society"},{"name":"International Antiviral Society\u2013USA"},{"name":"International Antiviral Society"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,7]]},"DOI":"10.1093\/cid\/ciy463","type":"journal-article","created":{"date-parts":[[2018,5,28]],"date-time":"2018-05-28T19:10:57Z","timestamp":1527534657000},"page":"177-187","source":"Crossref","is-referenced-by-count":180,"title":["Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society\u2013USA Panel"],"prefix":"10.1093","volume":"68","author":[{"given":"Huldrych F","family":"G\u00fcnthard","sequence":"first","affiliation":[{"name":"University Hospital Z\u00fcrich and Institute of Medical Virology, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Pierre et Marie Curie University and Piti\u00e9-Salp\u00eatrie\u0155e Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service and IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain"},{"name":"Africa Health Research Institute, KwaZulu Natal, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deenan","family":"Pillay","sequence":"additional","affiliation":[{"name":"University College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Shafer","sequence":"additional","affiliation":[{"name":"Stanford University Medical School, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie M","family":"Wensing","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"International Antiviral Society\u2013USA, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas D","family":"Richman","sequence":"additional","affiliation":[{"name":"Veterans Affairs San Diego Healthcare System and University of California San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,20]]},"reference":[{"key":"key\n\t\t\t\t2019010623582264300_CIT0001","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/cid\/ciw128","article-title":"Emergence of acquired HIV-1 drug resistance almost stopped in Switzerland: a 15-year prospective cohort analysis","volume":"62","author":"Scherrer","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0002","author":"World Health Organization"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0003","doi-asserted-by":"crossref","first-page":"e1001810","DOI":"10.1371\/journal.pmed.1001810","article-title":"Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis","volume":"12","author":"Rhee","year":"2015","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0004","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0005","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0006","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3851\/IMP2437","article-title":"Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review","volume":"18","author":"Stadeli","year":"2013","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0007","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","article-title":"HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study","volume":"11","author":"Hamers","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0008","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society\u2013USA panel","volume":"47","author":"Hirsch","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0009","first-page":"132","article-title":"2017 Update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2017","journal-title":"Top Antivir Med"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0010","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/cid\/civ963","article-title":"Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe","volume":"62","author":"Hofstra","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0011","doi-asserted-by":"crossref","first-page":"30436","DOI":"10.2807\/1560-7917.ES.2017.22.2.30436","article-title":"National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014","volume":"22","author":"Hauser","year":"2017","journal-title":"Euro Surveill"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0012","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hiv.12414","article-title":"Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom","volume":"18","author":"Tostevin","year":"2017","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0013","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/jac\/dkv049","article-title":"HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies","volume":"70","author":"Frange","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0014","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hiv.12236","article-title":"Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial","volume":"16","author":"Baxter","year":"2015","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAD.0000000000001689","article-title":"Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort","volume":"32","author":"Olson","year":"2018","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0016","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jiw165","article-title":"Successful prevention of transmission of integrase resistance in the Swiss HIV Cohort Study","volume":"214","author":"Scherrer","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0017","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2780","article-title":"Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013","volume":"20","author":"Stekler","year":"2015","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0018","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/QAD.0000000000000768","article-title":"A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK","volume":"29","author":"Mourad","year":"2015","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0019","doi-asserted-by":"crossref","first-page":"e5253","DOI":"10.1136\/bmj.e5253","article-title":"Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study","volume":"345","author":"Dolling","year":"2012","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/infdis\/jiv012","article-title":"Assessing the paradox between transmitted and acquired HIV Type 1 drug resistance mutations in the Swiss HIV Cohort Study from 1998 to 2012","volume":"212","author":"Yang","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP1749","article-title":"Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient","volume":"16","author":"Boyd","year":"2011","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0022","unstructured":"Hernandez AL , OcfemiaMCB, SaduvalaN, et al HIV integrase genotypic testing and resistance in the United States--9 jurisdictions (abstract 478). In: Program and Abstracts of the Conference on Retroviruses and Opportunistic Infections (2017). Seattle, Washington."},{"key":"key\n\t\t\t\t2019010623582264300_CIT0023","volume-title":"Guidelines on the public health response to pretreatment HIV drug resistance: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"World Health Organization","year":"2016","edition":"2"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0024","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jac\/dkw463","article-title":"Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis","volume":"72","author":"Boerma","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cit694","article-title":"Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study","volume":"58","author":"Drescher","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0026","doi-asserted-by":"crossref","first-page":"e1004722","DOI":"10.1371\/journal.ppat.1004722","article-title":"Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds","volume":"11","author":"Yang","year":"2015","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0027","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/cid\/civ732","article-title":"HIV-1 transmission during recent infection and during treatment interruptions as major drivers of new infections in the Swiss HIV Cohort Study","volume":"62","author":"Marzel","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0028","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/512088","article-title":"High rates of forward transmission events after acute\/early HIV-1 infection","volume":"195","author":"Brenner","year":"2007","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0029","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/590501","article-title":"HIV-1 transmission, by stage of infection","volume":"198","author":"Hollingsworth","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society\u2013USA panel","volume":"304","author":"Thompson","year":"2010","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0031","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society\u2013USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0032","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society\u2013USA Panel","volume":"312","author":"G\u00fcnthard","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0033","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society\u2013USA panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0034","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hiv.12322","article-title":"Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons","volume":"17","author":"Ryom","year":"2016","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0035","volume-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0036","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/JVI.02132-08","article-title":"Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants","volume":"83","author":"Abrahams","year":"2009","journal-title":"J Virol"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0037","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0038","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/cid\/cir725","article-title":"Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection","volume":"53","author":"Rieder","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0039","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jac\/dku426","article-title":"Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing","volume":"70","author":"Cozzi-Lepri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0040","doi-asserted-by":"crossref","first-page":"8359","DOI":"10.1128\/JVI.02582-10","article-title":"Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants","volume":"85","author":"Gianella","year":"2011","journal-title":"J Virol"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0041","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1086\/651136","article-title":"Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy","volume":"201","author":"Metzner","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0042","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1097\/QAD.0000000000000397","article-title":"Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients","volume":"28","author":"Metzner","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0043","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0044","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/AAC.00076-14","article-title":"Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients","volume":"58","author":"Ryscavage","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0045","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00023210-200216090-00002","article-title":"Clinical implications of CNS penetration of antiretroviral drugs","volume":"16","author":"Wynn","year":"2002","journal-title":"CNS Drugs"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0046","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1128\/AAC.05317-11","article-title":"Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients","volume":"55","author":"Baheti","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0047","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40262-014-0148-z","article-title":"Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention","volume":"53","author":"Trezza","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0048","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/POR.S127974","article-title":"Reduced adherence to antiretroviral therapy is associated with residual low-level viremia","volume":"8","author":"Maggiolo","year":"2017","journal-title":"Pragmat Obs Res"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0049","doi-asserted-by":"crossref","first-page":"ofw089","DOI":"10.1093\/ofid\/ofw089","article-title":"A single quantifiable viral load is predictive of virological failure in human immunodeficiency virus (HIV)-infected patients on combination antiretroviral therapy: the Austrian HIV Cohort Study","volume":"3","author":"Leierer","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0050","doi-asserted-by":"crossref","first-page":"1004.e9","DOI":"10.1016\/j.cmi.2016.08.012","article-title":"A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure","volume":"22","author":"Gonzalez-Serna","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0051","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","article-title":"HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure","volume":"28","author":"Swenson","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0052","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000331998","article-title":"The HIVdb system for HIV-1 genotypic resistance interpretation","volume":"55","author":"Tang","year":"2012","journal-title":"Intervirology"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0053","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cid\/ciu019","article-title":"Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals","volume":"58","author":"Gonzalez-Serna","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0054","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/jac\/dkx042","article-title":"Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies\/mL: a 2014 French nationwide study","volume":"72","author":"Assoumou","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0055","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"Taiwo","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0056","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/infdis\/jiw213","article-title":"No evidence that HIV-1 subtype C infection compromises the efficacy of tenofovir-containing regimens: cohort study in the United Kingdom","volume":"214","author":"White","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0057","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/135965350601100617","article-title":"HIV-1 subtypes and response to combination antiretroviral therapy in Europe","volume":"11","author":"Bannister","year":"2006","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0058","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/cid\/cis999","article-title":"Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy","volume":"56","author":"Chaix","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0059","first-page":"503","article-title":"Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis","volume":"30","author":"Antiretroviral Therapy Cohort Collaboration, Canadian Observational Cohort Collaboration, UK Collaboration HIV Cohort Study, Collaboration of Observational HIV Epidemiological Research in Europe","year":"2016","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0060","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3851\/IMP1697","article-title":"In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients","volume":"15","author":"Dierynck","year":"2010","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0061","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1086\/598502","article-title":"Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy","volume":"48","author":"Geretti","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0062","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/cid\/cir669","article-title":"Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B","volume":"53","author":"Scherrer","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0063","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/QAD.0b013e328348065a","article-title":"Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies","volume":"25","author":"Rockstroh","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0064","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/cid\/civ102","article-title":"Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial","volume":"60","author":"Kantor","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0065","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3018(16)00023-0","article-title":"Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden","volume":"3","author":"H\u00e4ggblom","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0066","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1758-2652-13-4","article-title":"Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy","volume":"13","author":"Easterbrook","year":"2010","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0067","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1097\/QAD.0b013e3283610ec7","article-title":"Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period","volume":"27","author":"Kyeyune","year":"2013","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0068","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciq248","article-title":"Update on human immunodeficiency virus (HIV)-2 infection","volume":"52","author":"Campbell-Yesufu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0069","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2013.12.001","article-title":"Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection","volume":"102","author":"Men\u00e9ndez-Arias","year":"2014","journal-title":"Antiviral Res"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0070","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/1471-2334-14-461","article-title":"Antiretroviral therapy response among HIV-2 infected patients: a systematic review","volume":"14","author":"Ekouevi","year":"2014","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0071","doi-asserted-by":"crossref","first-page":"e46181","DOI":"10.1371\/journal.pone.0046181","article-title":"Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 \u201cdeep\u201d sequencing","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0072","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/hiv.12170","article-title":"Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir\/ritonavir monotherapy","volume":"16","author":"Torres-Cornejo","year":"2015","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0073","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/cid\/cix542","article-title":"Should we be testing for baseline integrase resistance in patients newly diagnosed with human immunodeficiency virus","volume":"65","author":"Koullias","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0074","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1038\/s41598-017-11893-8","article-title":"Evolution of gag and gp41 in patients receiving ritonavir-boosted protease inhibitors","volume":"7","author":"Manasa","year":"2017","journal-title":"Sci Rep"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0075","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/cit105","article-title":"Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing","volume":"56","author":"Swenson","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0076","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/COH.0b013e328356e9da","article-title":"Next-generation sequencing to assess HIV tropism","volume":"7","author":"Swenson","year":"2012","journal-title":"Curr Opin HIV AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0077","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/cir493","article-title":"Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc","volume":"53","author":"Swenson","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0078","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jiq030","article-title":"Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients","volume":"203","author":"Swenson","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0079","first-page":"77","article-title":"European recommendations for the clinical use of HIV drug resistance testing: 2011 update","volume":"13","author":"Vandamme","year":"2011","journal-title":"AIDS Rev"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0080","doi-asserted-by":"crossref","first-page":"e0181357","DOI":"10.1371\/journal.pone.0181357","article-title":"Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation","volume":"12","author":"Paredes","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0081","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/135965350400900420","article-title":"Clinically validated genotype analysis: guiding principles and statistical concerns","volume":"9","author":"Brun-V\u00e9zinet","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0082","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/135965350400900102","article-title":"Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors","volume":"9","author":"Lanier","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0083","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","author":"Miller","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0084","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/AAC.00388-07","article-title":"Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients","volume":"51","author":"King","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/aid.2007.0173","article-title":"Resistance profile of darunavir: combined 24-week results from the POWER trials","volume":"24","author":"de Meyer","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0086","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/QAD.0b013e32833677ac","article-title":"Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies","volume":"24","author":"Vingerhoets","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0087","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0088","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1086\/600073","article-title":"Predictive value of HIV-1 genotypic resistance test interpretation algorithms","volume":"200","author":"Rhee","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0089","doi-asserted-by":"crossref","first-page":"e11505","DOI":"10.1371\/journal.pone.0011505","article-title":"Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time","volume":"5","author":"Frentz","year":"2010","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0090","doi-asserted-by":"crossref","first-page":"e61436","DOI":"10.1371\/journal.pone.0061436","article-title":"Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response","volume":"8","author":"Vercauteren","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0091","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000332009","article-title":"The evolution of drug resistance interpretation algorithms: ANRS, REGA and extension of resistance analysis to HIV-1 group O and HIV-2","volume":"55","author":"Eberle","year":"2012","journal-title":"Intervirology"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0092","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000331999","article-title":"HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge","volume":"55","author":"Obermeier","year":"2012","journal-title":"Intervirology"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0093","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1097\/QAD.0b013e32825a69e4","article-title":"The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors","volume":"21","author":"Fox","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0094","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/cid\/cit104","article-title":"HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe","volume":"56","author":"Charpentier","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jviromet.2007.05.009","article-title":"Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling","volume":"145","author":"Vermeiren","year":"2007","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0096","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1086\/597305","article-title":"Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database","volume":"199","author":"Altmann","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0097","doi-asserted-by":"crossref","first-page":"e1003203","DOI":"10.1371\/journal.pcbi.1003203","article-title":"The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients","volume":"9","author":"Beerenwinkel","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0098","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/QAI.0b013e31816d9bf4","article-title":"Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data","volume":"48","author":"Winters","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0099","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1093\/jac\/dkw217","article-title":"An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype","volume":"71","author":"Revell","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/AAC.48.2.437-443.2004","article-title":"Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1","volume":"48","author":"Parkin","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0101","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0102","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/ciu020","article-title":"Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels","volume":"58","author":"Santoro","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0103","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1001\/jama.279.24.1984","article-title":"Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society\u2013USA Panel","volume":"279","author":"Hirsch","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0104","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/QAD.0000000000000119","article-title":"The increasing genetic diversity of HIV-1 in the UK, 2002\u20132010","volume":"28","author":"UK Collaborative Group on HIV Drug Resistance","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrg1246","article-title":"The causes and consequences of HIV evolution","volume":"5","author":"Rambaut","year":"2004","journal-title":"Nat Rev Genet"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0106","author":"World Health Organization"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0107","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0108","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy","volume":"316","author":"Rodger","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0109","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV Infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0110","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"Danel","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0111","author":"European AIDS Clinical Society"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0112","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/ciw130","article-title":"Editorial commentary: HIV is putting up less resistance","volume":"62","author":"Richman","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019010623582264300_CIT0113","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/QAD.0000000000001692","article-title":"Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance","volume":"32","author":"Lodi","year":"2018","journal-title":"AIDS"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/2\/177\/27407379\/ciy463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T12:04:45Z","timestamp":1661342685000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/2\/177\/5055715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,20]]},"references-count":113,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,7,20]]},"published-print":{"date-parts":[[2019,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy463","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1,15]]},"published":{"date-parts":[[2018,7,20]]}}}